Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Accumulated Depreciation (2016 - 2022)

Historic Accumulated Depreciation for Spyre Therapeutics (SYRE) over the last 8 years, with Q4 2022 value amounting to $4.1 million.

  • Spyre Therapeutics' Accumulated Depreciation rose 4789.44% to $4.1 million in Q4 2022 from the same period last year, while for Dec 2022 it was $4.1 million, marking a year-over-year increase of 4789.44%. This contributed to the annual value of $4.1 million for FY2022, which is 4789.44% up from last year.
  • According to the latest figures from Q4 2022, Spyre Therapeutics' Accumulated Depreciation is $4.1 million, which was up 4789.44% from $2.8 million recorded in Q4 2021.
  • Over the past 5 years, Spyre Therapeutics' Accumulated Depreciation peaked at $4.1 million during Q4 2022, and registered a low of $752000.0 during Q4 2018.
  • Its 5-year average for Accumulated Depreciation is $2.1 million, with a median of $2.0 million in 2020.
  • As far as peak fluctuations go, Spyre Therapeutics' Accumulated Depreciation soared by 4029.26% in 2019, and later skyrocketed by 8796.21% in 2020.
  • Over the past 5 years, Spyre Therapeutics' Accumulated Depreciation (Quarter) stood at $752000.0 in 2018, then soared by 40.29% to $1.1 million in 2019, then surged by 87.96% to $2.0 million in 2020, then skyrocketed by 41.3% to $2.8 million in 2021, then soared by 47.89% to $4.1 million in 2022.
  • Its Accumulated Depreciation stands at $4.1 million for Q4 2022, versus $2.8 million for Q4 2021 and $2.0 million for Q4 2020.